The effectiveness of oral misoprostol compares to intravenous oxytocin in enhancing labor in primigravida: A comparative study
1 Department of Obstetrics and Gynecology, Uniosun Teaching Hospital, Osogbo, Osun state, Nigeria.
2 Department of Obstetrics and Gynecology, Federal Medical Center, Lafia Nasarawa State, Nigeria.
3 Department of Pharmacology and Therapeutics, University of Medical Sciences, Ondo, Ondo State, Ondo State
4 Department of Women’ s health, Watford General hospital, WHHT. United Kingdom.
Research Article
GSC Advanced Research and Reviews, 2024, 20(02), 077–087.
Article DOI: 10.30574/gscarr.2024.20.2.0256
Publication history:
Received on 02 June 2024; revised on 19 July 2024; accepted on 22 July 2024
Abstract:
Background: Augmentation of labor addresses uterine inertia in primigravidae, with oxytocin being preferred. Misoprostol offers cost-effective, convenient alternatives, making it a cost-effective option.
Objective: The study evaluates the effectiveness and safety of misoprostol oral solution vs. oxytocin for primigravida augmentation.
Methodology: A randomized comparative study was conducted on primigravida in active labor in Osogbo metropolis, using three hospitals as study sites. The study included two arms: oxytocin-augmented and misoprostol-oral solution. Events in labor with fetal/maternal outcomes were monitored and documented. Appropriate statistical tests and presentations were applied, p value was set at <0.05
Result: A study of 159 patients on each arm of Oxytocin (oxy) and misoprostol (miso) was conducted, with the majority aged between 20-35 years (64.47%). The onset of adequate contractions interval was 8.73 and 9.03 minutes in Oxy and Miso arm, respectively while vaginal delivery intervals were 4.69 and 4.47 hours in the Oxy and Miso arms, respectively. Fetal Heart Rate abnormalities were more in the Miso arm but did not affect fetal outcomes. There was no significant difference in maternal outcomes, with vaginal delivery rate, caesarean section rate, postpartum hemorrhage reported estimated blood and Birth weight (p>0,005). Most neonates had a good APGAR score at birth. Stillbirth and intrauterine fetal death were not recorded. Vomiting was the only symptom with a significant more in the miso arm (p-value= 0.033),
Conclusion: Misoprostol, a 20mcg oral solution, is effective and safe for augmentation of labor in primigravidae during active labor phases, with side effects like vomiting.
Keywords:
Oxytocin; Misoprostol; Augmentation of labour; Primigravida
Full text article in PDF:
Copyright information:
Copyright © 2024 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0
